CRHR2抗体;CRHR2 Antibody—艾普蒂

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane 1-2: NIH/3T3 cells, mouse brain tissue, Primary antibody: P11682(CRHR2 Antibody) at dilution 1/650, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 10 minutes    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P11682(CRHR2 Antibody) at dilution 1/25. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using P11682(CRHR2 Antibody) at dilution 1/25. (Original magnification: ×200)    

  
  

Corticotropin-releasing hormone receptor 2 (CRHR2) is a G protein-coupled receptor that binds corticotropin-releasing hormone (CRH) and related peptides, playing a key role in modulating stress responses, anxiety, and energy homeostasis. It is widely expressed in the brain, cardiovascular system, and peripheral tissues, with distinct isoforms (CRHR2α, CRHR2β) arising from alternative splicing. CRHR2 activation influences diverse physiological processes, including appetite regulation, immune function, and cardiovascular adaptation, often counterbalancing the effects of its paralog, CRHR1. Dysregulation of CRHR2 signaling has been implicated in stress-related disorders, metabolic syndromes, and heart diseases.

CRHR2 antibodies are essential tools for investigating receptor localization, expression levels, and signaling mechanisms in both physiological and pathological contexts. These antibodies are designed to target specific epitopes within extracellular or intracellular domains, enabling applications such as immunohistochemistry, Western blotting, and flow cytometry. Species-specific variants (e.g., human, mouse, rat) are critical due to sequence divergence across models. Validation parameters, including knockout controls and peptide blocking assays, are crucial to ensure specificity, given the structural similarities between CRHR2 and other GPCRs. Recent studies using CRHR2 antibodies have clarified its neuroprotective roles and therapeutic potential in anxiety and heart failure, driving interest in drug development targeting this receptor.